# A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

> **NCT05200442** · PHASE1,PHASE2 · SUSPENDED · sponsor: **University of Chicago** · enrollment: 53 (estimated)

## Conditions studied

- Colorectal Cancer
- Colorectal Adenocarcinoma
- Colorectal Cancer Metastatic
- Advanced Colorectal Carcinoma
- Advanced Colorectal Adenocarcinoma

## Interventions

- **DRUG:** VS-6766/avutometinib
- **DRUG:** Cetuximab
- **OTHER:** Pill Diary

## Key facts

- **NCT ID:** NCT05200442
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-08-22
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 53 (ESTIMATED)
- **Why stopped:** enrollment goal met pending determination of evaluable subjects
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200442, "A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT05200442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*